Reye syndrome in children receiving salicylate therapy for connective tissue disease.
Concern that salicylates may play a role in the pathogenesis of Reye syndrome has raised the question of whether children receiving salicylate therapy for connective tissue disease are at risk for development of Reye syndrome. Of 176 patients with biopsy-confirmed Reye syndrome studied between January 1969 and June 1983, six had connective tissue disease at the time of development of Reye syndrome, and all six were receiving salicylates. Compared with the general population, children receiving salicylate therapy for connective tissue disease may be at increased risk for the development of Reye syndrome.
D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D003240:Connective Tissue Diseases / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D011446:Prospective Studies; D012202:Reye Syndrome / Q000139:chemically induced* / Q000473:pathology; D012306:Risk; D012459:Salicylates / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors
D012459:Salicylates